Recordati : Recordati further strengthens rare diseases franchise
>Acquisition of Enjaymo in cold agglutinin disease - Recordati on Friday announced a fresh acquisition for € 825m (+ up to € 250m in commercial milestones) with Enjaymo (sutimlimab), a monoclonal antobody developed by Sanofi in the treatment of cold agglutinin disease, a rare form of anaemia. The treatment, the only drug specifically approved in this indication, has generated sales of € 100m over the last 12 months (in the US, Europe and Japan).We see this a stra...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.